期刊文献+

调脂药物的联合应用及安全性监测 被引量:4

Combination of Lipid-Lowering Drugs and the Safety Monitoring
原文传递
导出
摘要 血脂异常是动脉粥样硬化性心脑血管疾病的重要危险因素。他汀类药物通过降低低密度脂蛋白胆固醇水平,使心血管事件明显减少。但是即使采用大剂量的他汀类药物仍难以达到指南要求的血脂水平标准,因此针对合并糖尿病、代谢综合征等心血管高危人群,他汀类药物联合贝特类、烟酸类、胆固醇吸收抑制药等药物成为临床上的重要选择。 Dyslipidemia is an important risk factor for atherosclerotic cardio-cerebro-vascular diseases.Clinical studies have shown that statins could significantly reduced cardiovascular events by reducing the level of low density lipoprotein cholesterol.However,it is difficult to achieve standard serum lipid levels recommended by guideline even with high doses of statins.For high-risk groups with diabetes or metabolic syndrome,the combination of statins and fibrates,niacin,cholesterol absorption inhibitors would be a preferable alternative in clinical.
出处 《临床药物治疗杂志》 2013年第1期38-41,共4页 Clinical Medication Journal
关键词 他汀类药物 贝特类 烟酸 依折麦布 联合 statins fibrates niacin ezetimibe combination
  • 相关文献

参考文献16

  • 1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5227
  • 2Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial) [ J ] . Am J Cardiol, 2005, 95(4): 462-468.
  • 3Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT- 335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipldemia [ J ] . Am J Cardiol, 2009,103(4): 515-522.
  • 4The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus [ J ] . N Engl J Med, 2010, 362(17): 1563-1574.
  • 5Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin [ J ] . Am J Cardiol, 2005, 95(1): 120-122.
  • 6Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [ J ] . N Engl J Med, 2001, 345(22): 1583-1592.
  • 7Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study [ J ] . Am J Cardiovasc Drugs, 2008, 8(2): 69-81.
  • 8AIM-HIGH Investigator, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy [ J ] . N Engl J Med, 2011 , 365(24): 2255-2267.
  • 9Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial [ J ] . Mayo Clin Proc, 2005,80(5): 587-595.
  • 10Winkler K, Jacob S, Muller-Schewe T, et al. Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus [ J ] . Atherosclerosis, 2012, 220(1): 189-193.

二级参考文献149

共引文献5226

同被引文献45

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部